Objective To investigate the efficacy and safety of Finelidone in treating diabetic nephropathy by ameliorating the body's inflammatory state and renal function indicators.Methods 72 patients with diabetic nephropathy who visited the Blood Purification Center of Xuchang Central Hospital from January 2021 to January 2024 were randomly divided into a control group and a study group,with 36 cases in each group.The control group received conventional treatment,while the study group was additionally administered Finelidone on the basis of the control group's regimen.Serum creatinine(Scr),urinary albumin-to-creatinine ratio(ACR),serum interleukin-6(IL-6),serum tumor necrosis factor-α(TNF-α),and overall effective rate were compared between the two groups before and after treatment.Results After 12 weeks of treatment,the study group exhibited significantly lower levels of Scr,ACR,IL-6,and TNF-α than the control group,with an overall effective rate of 80.56%higher than the control group's overall effective rate of 55.56%.These differences were statistically significant(P＜0.05).Conclusion Finelidone ameliorates renal function and clinical symptoms in patients with diabetic nephropathy by suppressing the body's inflammatory response and demonstrates good safety.The adjunctive use of Finelidone with conventional treatment can confer greater benefits to patients with diabetic nephropathy,thereby decelerating disease progression and improving long-term prognosis,warranting its promotion in clinical practice.
维普
万方数据